PF582 (ranibizumab biosimilar) / Ligand 
Welcome,         Profile    Billing    Logout  
 4 Diseases   0 Trials   0 Trials   13 News 
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron
    Review, Journal:  Pipeline therapies for neovascular age related macular degeneration. (Pubmed Central) -  Oct 3, 2021   
    Those in the pipeline of VEGF targets include abicipar pegol (Abicipar; Allergan, Coolock, Dublin), OPT-302 (Opthea; OPTHEA limited; Victoria, Melbourne), conbercept (Lumitin; Chengdu Kanghong Pharmaceutical Group, Chengdu, Sichuan), and KSI-301 (Kodiak Sciences, Palo Alto, CA)...Gene therapy present possible longer treatments options as well and are reviewed here. This paper will highlight the past approved medications as well as pipeline therapies for neovascular AMD.
  • ||||||||||  PF582 (ranibizumab biosimilar) / Ligand
    Trial completion, Trial primary completion date:  Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration (clinicaltrials.gov) -  May 11, 2016   
    P1/2,  N=25, Completed, 
    This paper will highlight the past approved medications as well as pipeline therapies for neovascular AMD. Trial primary completion date: May 2016 --> Jan 2016 | Active, not recruiting --> Completed
  • ||||||||||  PF582 (ranibizumab biosimilar) / Ligand
    Enrollment closed, Trial primary completion date:  Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration (clinicaltrials.gov) -  May 5, 2016   
    P1/2,  N=25, Active, not recruiting, 
    Trial primary completion date: May 2016 --> Jan 2016 | Active, not recruiting --> Completed Completed --> Active, not recruiting | Trial primary completion date: Dec 2015 --> May 2016